Safety and Efficacy of NK510 to Treat NSCLC

Exploratory Study of NK510 Combined With PD-1 Blockade in the Treatment of Relapsed and Refractory Advanced NSCLC

This study will evaluate the safety and efficacy of NK510 in the treatment of relapsed and refractory advanced NSCLC.NK510 will be administered in combination with PD-1 blockade. Patients are required to undergo a biopsy for confirmation of tumor PD-L1 expression,and EGFR,ROS1,ALK gene must be negative. The safety and efficacy of this treatment will be evaluated.

Study Overview

• Status: Recruiting
• Conditions: NSCLC
• Intervention / Treatment: Drug: NK510; Drug: Tislelizumab，atezolizumab or sugemalimab

• Study Type: Interventional
• Enrollment (Estimated): 9
• Phase: Early Phase 1

Contacts and Locations

• Study Contact: Name: Jun Yan, PhD; Phone Number: +86 186 2166 8515; Email: yanjun@basetherapeutics.com
• Study Contact Backup: Name: Tangfeng Lv; Phone Number: +86 139 5201 6932; Email: bairoushui@163.com

Study Locations

• China
  • Jiangsu
    • Nanjing, Jiangsu, China
      • Recruiting
      • General Hospital of eastern theater command
      • Contact: Tangfeng Lv; Phone Number: +86 139 5201 6932; Email: bairoushui@163.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• age≥18 years;
• Epidermal growth factor receptor (EGFR) gene mutation negative, ROS oncogene 1 (ROS1) negative, and anaplastic lymphoma kinase (ALK) negative, stage III or IV non-small cell lung cancer that cannot be operated on or treated with radiotherapy, locally advanced or relapsed or metastatic non-small cell lung cancer;
• Biopsy tissue or pathological sections can be obtained, and tumor PD-L1 expression is positive (defined as ≥ 1% of TPS);
• After receiving ≥ 4 courses of PD-1 monoclonal antibody ± chemotherapy in the past, the disease is currently in a stable or progressive state;
• According to RECIST v1.1 (Solid Tumor Efficacy Evaluation Criteria), there is at least one CT scan measurable lesion present;
• ECOG physical status score of 0-2;
• Expected survival >=3 months;
• Except for hair loss and fatigue, all AE after anti-tumor treatments have alleviated toxicity to level 1 (CTCAE v5.0) or original baseline;
• Female of childbearing age must be non lactating and have a negative serum pregnancy test within 1 week prior to enrollment;
• Voluntarily sign an informed consent form to participate in this study.

Exclusion Criteria:

• Pregnant or lactating female patients;
• Patients with central nervous system metastasis (CNS) and/or cancerous meningitis and obvious symptoms;
• Other malignancies have been diagnosed within 3 years prior to the first use of the study drug;
• Subjects with active, known or suspected autoimmune diseases [excluding type I diabetes, hypothyroidism requiring hormone replacement therapy only, skin diseases not requiring systemic treatment (such as vitiligo, psoriasis or alopecia) or diseases that are not expected to recur without external triggers;
• subjects have a history of immune deficiency, including HIV testing positive, or other acquired or congenital immune deficiency diseases or organ transplantation history;
• Have a history of serious cardiovascular and cerebrovascular diseases, including but not limited to: severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, third degree atrioventricular block, etc; At rest, the QTc interval obtained from a 12 lead electrocardiogram examination is>480 ms; Acute coronary syndrome, congestive heart failure, aortic dissection, stroke, or other Grade 3 or above cardiovascular and cerebrovascular events occurred within 6 months prior to enrollment; The New York Heart Association (NYHA) has a heart function rating of ≥ II or a left ventricular ejection fraction (LVEF) of<50%; Clinically uncontrollable hypertension;
• Radical radiotherapy was performed within 4 weeks prior to enrollment; Local palliative radiotherapy or Chinese herbal medicine/traditional Chinese patent medicines and simple preparations with anti-tumor indications within 2 weeks before enrollment;
• Not fully recovered from major surgery or trauma within 2 weeks prior to enrollment;
• Participated in research drug trials and received research treatment or used research instruments within 4 weeks before enrollment;
• Other anti-tumor treatments outside of this research protocol are currently underway or planned;
• Received blood transfusion, erythropoietin, granulocyte colony stimulating factor (G-CSF), or granulocyte macrophage colony stimulating factor treatment within 2 weeks prior to enrollment;
• Subjects who received systemic treatment with corticosteroids (prednisone>10 mg/day or equivalent) or other immunosuppressive/enhancing drugs (such as thymosin, interleukin-2, and interferon) within 2 weeks prior to enrollment. Allowing selected subjects to inhale or topically use corticosteroids in the absence of active autoimmune diseases;

• The virological examination of hepatitis B or hepatitis C during screening meets any of the following criteria:

  1. HBsAg positive and peripheral blood HBV-DNA titer detection≥1×10^3 copies/mL or upper limit of normal value;
  2. HCV antibody positive;
• Subjects who are known to be allergic or intolerant to PD-1 monoclonal antibody.

• Meet any of the following standards:

  1. Hematological:Neutrophil count <1.5×10^9/L; Platelet count < 75×10^9/L; Hemoglobin < 9 g/dL;
  2. Hepatic:ALT > 3 × ULN (tumor liver metastasis ≥ 5×ULN); AST > 3×ULN (tumor liver metastasis ≥ 5×ULN); TBIL > 1.5 ×ULN or TBIL>2.5 × ULN (3.0 mg/dL) in Gilbert syndrome subjects;
  3. Renal:Serum creatinine > 1.5 × ULN or creatinine clearance < 50mL/min;
• Any uncertain factors that affect the safety or compliance of patients.
• Investigators believe that any other serious or uncontrollable medical disease, active infection, abnormal physical examination, laboratory examination, mental state change, or mental illness increases the risk of the subject or affects the research results.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Group A (low-dose group); NK510 will be administered once a week for a total of six weeks.1×10^9 NK cells/dose. PD-1 blockade will be administered every 3 weeks.	Drug: NK510; Intravenous infusion; Drug: Tislelizumab，atezolizumab or sugemalimab; Administer according to the instructions
Experimental: Group B (medium-dose group); NK510 will be administered once a week for a total of six weeks.9×10^9 NK cells/dose. PD-1 blockade will be administered every 3 weeks.	Drug: NK510; Intravenous infusion; Drug: Tislelizumab，atezolizumab or sugemalimab; Administer according to the instructions
Experimental: Group C (high-dose group); NK510 will be administered once a week for a total of six weeks.12×10^9 NK cells/dose. PD-1 blockade will be administered every 3 weeks.	Drug: NK510; Intravenous infusion; Drug: Tislelizumab，atezolizumab or sugemalimab; Administer according to the instructions

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Dose-Limiting Toxicity	To evaluate the DLT during N510 treatment	6 weeks
Maximal Tolerable Dose	to evaluate the MTD of NK510	6 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall response rate (ORR) after administration	Effectiveness Metrics	6 weeks

Collaborators and Investigators

• Sponsor: Base Therapeutics (Shanghai) Co., Ltd.
• Collaborators: The General Hospital of Eastern Theater Command
• Investigators: Principal Investigator: Tangfeng Lv, PhD, The General Hospital of Eastern Theater Command

Study record dates

Study Major Dates

• Study Start (Actual): July 1, 2023
• Primary Completion (Estimated): July 1, 2024
• Study Completion (Estimated): July 1, 2024

Study Registration Dates

• First Submitted: October 17, 2023
• First Submitted That Met QC Criteria: October 17, 2023
• First Posted (Actual): October 24, 2023

Study Record Updates

• Last Update Posted (Actual): October 25, 2023
• Last Update Submitted That Met QC Criteria: October 23, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Neoplasms; Lung Diseases; Neoplasms by Site; Respiratory Tract Neoplasms; Thoracic Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Antineoplastic Agents, Immunological; Immune Checkpoint Inhibitors; Atezolizumab; Tislelizumab
• Other Study ID Numbers: NK510-06

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No